Your session is about to expire
← Back to Search
Tailored Light Therapy for Dementia
N/A
Recruiting
Led By Mariana G Figueiro, PhD
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Mild to moderate Alzheimer's disease and related dementia (ADRD)
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline (week 0) and intervention (week 4)
Awards & highlights
Study Summary
This trial shows that tailored light treatment can improve sleep, reduce depression and reduce agitation in people with Alzheimer's disease and related dementia.
Who is the study for?
This trial is for individuals with mild to moderate Alzheimer's disease and related dementia. It's not suitable for those who are blind, have major organ failure or illness, a history of head injury, uncontrolled hypertension or diabetes, use sleep aid medicine, or have obstructing cataracts or macular degeneration.Check my eligibility
What is being tested?
The study tests whether tailored light treatment can improve sleep efficiency, reduce depression symptoms, and lessen agitation in people with dementia. Participants will receive either an active light intervention designed just for them or a placebo-like inactive one.See study design
What are the potential side effects?
Since the trial involves light therapy rather than medication, side effects may be minimal but could include potential discomfort from the light exposure such as eye strain or headache.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with mild to moderate Alzheimer's or related dementia.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline (week 0) and intervention (week 4)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline (week 0) and intervention (week 4)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Agitation
Depression
Sleep Disturbance
Secondary outcome measures
Actigraphy
Activity of Daily Living
Light/dark patterns
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Active InterventionActive Control1 Intervention
Light levels, primary and secondary measurements are obtained after a 4-week intervention period where active lighting is experienced by patients.
Group II: Inactive interventionPlacebo Group1 Intervention
Light levels, primary and secondary measurements are obtained after a 4-week intervention period where an inactive lighting is experienced by patients
Find a Location
Who is running the clinical trial?
National Institute on Aging (NIA)NIH
1,675 Previous Clinical Trials
28,020,880 Total Patients Enrolled
36 Trials studying Depression
28,308 Patients Enrolled for Depression
Icahn School of Medicine at Mount SinaiLead Sponsor
861 Previous Clinical Trials
525,231 Total Patients Enrolled
34 Trials studying Depression
4,324 Patients Enrolled for Depression
Mariana G Figueiro, PhDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
2 Previous Clinical Trials
76 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with mild to moderate Alzheimer's or related dementia.My major organs are functioning properly.I have macular degeneration.I have had a head injury in the past.You are unable to see.You have a serious medical condition.I have cataracts that block my vision.I am currently taking medication to help me sleep.I have high blood pressure or diabetes.
Research Study Groups:
This trial has the following groups:- Group 1: Active Intervention
- Group 2: Inactive intervention
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the enrollment capacity of this experiment?
"Affirmative. Evidence found on clinicaltrials.gov indicates that this investigation, which was initially published on January 1st 2020, is currently enrolling volunteers. 45 individuals need to be recruited from 5 different sites."
Answered by AI
Is this trial still recruiting participants?
"Affirmative. According to the information available on clinicaltrials.gov, this medical experiment is now open for enrolment and was initially posted in 2020. The trial necessitates 45 participants from 5 distinct sites, with its most recent update taking place at the end of 2022."
Answered by AI
How many locales are hosting this clinical trial?
"Five trial sites are enrolling patients for this clinical study, with Hawthorne Ridge in East Greenbush, Icahn School of Medicine at Mount Sinai in Troy and Teresian House in New york all participating. Additionally, there are another 5 medical centres actively recruiting participants."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger